Overview

NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis

Status:
Completed

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the impact of treatment with a non-steroidal anti-inflammatory drug (NSAID) - Celecoxib - when added to anti-tumour necrosis factor (TNF) therapy - Golimumab - as compared to anti-TNF therapy (Golimumab) alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis (AS).

Phase:

Phase 4

Details

Lead Sponsor:

Charite University, Berlin, Germany

Treatments:

Antibodies, Monoclonal
Celecoxib
Golimumab